2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 388-390
Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric
PAPER

1051 Safety and efficacy of the first CD19/BCMA dual-targeting in vivo CAR-T (QI-019A) for R/R multiple myeloma: A phase 1 study

Jia Xu, Liman Su2, Lin Liu3, Yingyong Xu, MD, PhD, MBA4, Weijiayi Wang5, Chunyan Sun, MD6, Wei Xie7, xiaoling wang8, jie zhou9, Jiapan Hu10, yixuan zhou11, Ming Jin12, xiaobin song13, Hu Yu, MD14, Luhan Yang, PhD15, Heng Mei, MD, PhD16
1 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Qihan Biotechnology, Hangzhou, China
5 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 Qihan Biotechnology, Hangzhou, China
9 Qihan Biotechnology, Hangzhou, China
10 Qihan Biotechnology, Hangzhou, China
11 Qihan Biotechnology, Hangzhou, China
12 Qihan Biotechnology, Hangzhou, China
13 Qihan Biotechnology, Hangzhou, China
14 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 Qihan Biotechnology, Hangzhou, China
16 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Introduction: Ex vivo CAR-T has shown unprecedented efficacy in treating relapsed/refractory multiple myeloma (R/R MM), but the production complexity renders it costly and inaccessible. Built on the ClariT platform, QI-019A represents the first in vivo dual-targeting CAR-T for R/R MM, delivering a nanobody-derived CD19/BCMA CAR to CD3+ T cells directly. The platform leverages Macroi-293 cells to mitigate post-infusion vector clearance, alongside a CAR-less design that suppresses premature CAR expression during packaging. The dual-targeting strategy enables the comprehensive eradication of myeloma cells and their progenitors, thereby promoting more durable responses. Herein, we report the preliminary results of the phase 1, open-label study with QI-019A in treating 9 patients with R/R MM (NCT07429721).

Methods: Adult patients with measurable disease who have undergone ≥2 lines of prior therapies, with ECOG score 0-2 and estimated survival >3 months, will be enrolled. Prior BCMA-targeted therapies are allowed. All participants will receive the intravenous infusion of QI-019A without lymphodepletion, and the dose escalation employs a rapid titration design.

Results: As of August 2026, a total of 9 patients with R/R MM received QI-019A at two dose levels (DL1 and DL2), with doses ranging from 2.0 to 9.0 × 108TUs. The median age was 59 years (range, 48-79), and patients had undergone a median of 3 prior lines of therapy (range, 2-6). Notably, 1 patient had relapsed 2 years after prior BCMA-targeted CAR-T therapy, and 2 others progressed after anti-CD3/BCMA/GPRC5D tri-specific T-cell engager (TCE) treatment. At baseline, 5 patients presented with paraosseous plasmacytomas, and 5 patients had triple-class refractory disease.

The median screening-to-infusion time was 8 days (range, 1-22). No dose-limiting toxicity or treatment-related deaths were reported. After infusion, circulating vector load peaked at 5 min to 2 h and cleared within 24 h. Vector-related reactions, predominantly fever and chills, occurred in 4/9 (44.4%) patients and resolved within 2 days. No significant activation of the complement system during this period was detected. Grade 1 CRS developed in 7/9 (77.8%) patients, and no ICANS and IEC-HS was observed. Grade 3-4 anemia (1/9, 11.1%), thrombocytopenia (3/9, 33.3%), leukopenia (6/9, 66.7%), lymphocytopenia (6/9, 66.7%), and neutropenia (6/9, 66.7%) were recorded. All patients exhibited a lymphocyte decrease by day 1, albeit to varying degrees. Treatment-emergent infection was only observed in 1 patient.

Patients in the high-dose group exhibited faster CAR-T expansion and higher peak levels than the low-dose group. In the DL1 cohort (n=3), CAR-T cells peaked on day 14 (range, 10-17), with a median Cmax of 13,422 copies/μg DNA (range, 1,671-29,130). For DL2 (n=6), the peak occurred earlier at day 11 (range, 10-17), with a median Cmax of 41,401 copies/μg DNA (range, 4,623-75,785). Notably, 2 of the 3 patients with prior BCMA-targeted therapies achieved robust expansion, with Cmax of 13,422 and 75,785 copies/μg DNA. Flow cytometry confirmed T cell-specific CAR transduction, with CAR-T cells at peak expansion displaying predominantly central memory and effector memory phenotypes. In bone marrow BCMA+ cells, the CAR transgene was detectable, yet CAR protein expression was absent, further supporting the specificity.

At a median follow-up of 2.0 months (range, 1.0-4.5), QI-019A achieved a rapid, deep, and durable response in 7/8 evaluable patients, including 4 sCR, 1 VGPR, 1 PR, 1MR. All evaluable patients with ≥1 month follow-up attained bone marrow MRD negativity (10-5), and blood/urine free light chains normalized within 2 months. Notably, among patients previously treated with BCMA-targeted CAR-T and TCE (n=3), 2 achieved sCR, accompanied by regression of paraosseous plasmacytomas.

Conclusions: QI-019A is a first-in-class in vivo CD19/BCMA dual-targeting CAR-T therapy. It demonstrated a favorable outpatient-level safety profile, with no severe CRS, ICANS, or HLH observed. In heavily pretreated patients, including those had prior exposure to BCMA-targeted therapies, QI-019A induced rapid and deep antitumor responses, with all evaluable patients achieving MRD negativity. The streamlined 8-day screening-to-infusion timeline further enhances treatment accessibility. This ongoing study continues to enroll patients to further define the long-term efficacy, durability, and feasibility of outpatient administration.

Heng Mei, MD, PhD: No relevant conflicts of interest to declare.